Interferon regulatory factor-1 (IRF-1) acts as a transcriptional activator in the interferon system and as a tumor suppressor. The loss of functional IRF-1 has been observed in a signi®cant number of patients with myelodysplastic syndrome (MDS) and leukemia, suggesting a potentially critical role of IRF-1 in human oncostasis. Here we report an alternative mechanism by which IRF-1 may be inactivated. We puri®ed an IRF-1 association molecule which was revealed to be identical to a nuclear factor nucleophosmin (NPM)/B23/numatrin. Functional analysis showed that NPM inhibited the DNA-binding and transcriptional activity of IRF-1. Moreover, NPM was overexpressed in several clinical leukemia samples and human-derived leukemia cell lines. Finally, overexpression of NPM in NIH3T3 cells resulted in malignant transformation. These results suggest the possible involvement of NPM in inactivating IRF-1-dependent anti-oncogenic surveillance in human cancer development.
Introduction
Interferon regulatory factor-1 (IRF-1) and -2 (IRF-2) were initially identi®ed as regulators of the interferon system. IRF-1 acts as a transcriptional activator of interferon-a/b and many interferon regulated genes, whereas IRF-2 functions as a transcriptional repressor by competing for binding to the same DNA sequence elements (IRF-Es) (Miyamoto et al., 1988; Harada et al., 1989 Harada et al., , 1990 . Recent studies using IRF-1 knockout mice revealed that IRF-1 plays a role in induction of several IFN-inducible genes and of the anti-viral state by interferons (Matsuyama et al., 1993; Kamijo et al., 1994; Kimura et al., 1994) , suggesting that IRF-1 is a critical factor in several host defense mechanisms.
We have more recently demonstrated the role of IRF-1 as a tumor-suppressor: (i) NIH3T3 cells are transformed by IRF-2 overexpression and this transformed phenotype is reverted by concomitant overexpression of IRF-1 . (ii) Primary embryonic ®broblasts (EFs) from IRF-1 knockout (IRF-1 7/7 ) mice are susceptible to transformation by an activated form of c-Ha-ras alone (Tanaka et al., 1994a) . (iii) IRF-1 suppresses tumorigenicity of cells transformed by c-myc or fos-B . The expression level of IRF-1 is the highest at the G1-arrested stage of cell cycle, whereas the level of IRF-2 is constant throughout . Moreover, it has been demonstrated that IRF-1 is involved in DNA damage-induced apoptosis and cell cycle arrest (Tanaka et al., 1994a (Tanaka et al., , 1996 Tamura et al., 1995) . Collectively these facts indicate that IRF-1 plays a role in cell growth control and surveillance against cancer development.
The human IRF-1 gene has been mapped to 5q31.1 (Willman et al., 1993; Harada et al., 1994a) . This region of the chromosome often exhibits deletions in cases of myelodysplastic syndrome (MDS) and secondary leukemia (Le Beau et al., 1986 . It was demonstrated that one or both alleles of the IRF-1 gene were deleted in each of 13 studied cases of MDS and leukemia with 5q deletion or translocation of 5q31 (Willman et al., 1993) . In addition, another mechanism of inactivation of IRF-1, accelerated exon-skipping by alternative splicing, has been observed. The exon skipped form of IRF-1 lacks DNA-binding activity, and cannot manifest anti-tumor activity. As a result, approximately 30% of patients with MDS or overt leukemia from MDS showed inactivation of IRF-1 (Harada et al., 1994b) . On the other hand, the examination of several human leukemia cell lines revealed that at least one allele of IRF-1 gene remained and the intact form of IRF-1 mRNA was still detectable (T Kondo, unpublished data). This fact raises the possibility of another mechanism by which cells escape IRF-1-dependent anti-tumor surveillance in human cancer development. For example, p53, one of the most well-known tumor-suppressor, is often inactivated in human neoplasia due to deletions or point mutations of its structural gene. Inactivation of p53 also occurs by binding to viral oncoproteins or to MDM2 (reviewed in Vogelstein and Kinzler, 1992) . Viral oncogenes such as SV40 T antigen inactivate p53 function by direct interaction with p53. Inactivation of a tumor suppressor gene by binding to a viral oncoprotein is also observed in the case of the Rb protein (reviewed in Weinberg, 1991) . In addition, MDM2 can bind to p53 resulting in its functional inactivation, and ampli®cation of the MDM2 gene is often detected in human sarcomas (Oliner et al., 1992) . Therefore, we considered the possibility that the tumor suppressor function of IRF-1 may also be regulated by binding to another factor(s).
Here we identi®ed an IRF-1-binding protein which is identical to nucleophosmin (NPM). NPM was ®rst reported as a non-ribosomal nucleolar phosphoprotein, and is highly expressed in leukemia cell lines (Feuerstein et al., 1988) . In this study, NPM inhibited the DNA-binding activity and the transcriptional activity of IRF-1. We also observed that NPM is overexpressed in some cases of clinical leukemia and leukemia cell lines. Moreover, by overexpression of NPM, NIH3T3 cells became transformed and displayed tumorigenicity in nude mice. Therefore, we suggest NPM may function in a mechanism of human neoplasia which allows cells to escape the anti-tumor surveillance of IRF-1.
Results

Identi®cation of IRF-BP and its possible role in cell growth
To identify IRF-1-associated molecule, we used glutathione S-transferase IRF-1 fusion protein (GST-IRF-1). Metabolically labeled nuclear and cytoplasmic extracts from human CML-derived cell line K-562 were incubated with glutathione-sepharose beads bound with GST-IRF-1 and the associated proteins were resolved on SDS ± PAGE. In this experiment, a 38 kDa protein was detected mainly in the nuclear fraction ( Figure 1a ). As IRF-1 is a nuclear transcriptional factor, we focused onto this 38 kDa protein, which we designated as IRF-1 binding protein (IRF-BP). In subsequent experiments, IRF-BP was also detected in the nuclear fraction of HeLa cells, suggesting that its expression is not limited to K-562 cells (data not shown). Previously, it has been shown that IRF-1 is a regulator of cell growth and may play the role in G1-arrested stage of the cell cycle . These facts led us to address the expression level of IRF-BP during the cell cycle. WI 38 cells, diploid human ®broblasts, were metabolically labeled in exponentially growing and G1-arrested stages. Each nuclear extract was subjected to GST-IRF-1 binding analysis (Figure 1b) . IRF-BP was clearly detected in the exponentially growing phase, whereas the level of IRF-BP was almost undetectable in growth arrested state. This result implies that IRF-BP may act contrary to IRF-1 activity in cycling cells.
IRF-BP is identical to nucleophosmin (NPM)/B23/numatrin
To characterize IRF-BP, we puri®ed IRF-BP protein by the GST-IRF-1 anity chromatography. Puri®ed protein was digested by lysyl endopeptidase, then the fragments of digested peptide were isolated (see Materials and methods). Five arbitrarily chosen fragments were sequenced and all of the determined sequences were identical to parts of the sequence of nucleophosmin (NPM), also called as B23 and numatrin, which is known as a nucleolar phosphoprotein (Table 1) . NPM was previously reported to be . . . AKFINYVKNCF . . .
Inactivation of IRF-1 by NPM
T Kondo et al regulated in cell cycle and expressed at the highest level in late G1 stage, and to be highly expressed in cancer cell lines (Feuerstein et al., 1988; Chan et al., 1989) .
NPM interferes with IRF-1 binding to target DNA sequences and attenuates the transcriptional activity of IRF-1
To address the role of NPM in IRF-1 action, we performed electrophoretic mobility shift analysis (EMSA). Surprisingly, the shifted band containing IRF-1 was diminished when NPM was added into the reaction mixture ( Figure 2a ). In this experiment, both IRF-1 and NPM were highly puri®ed (see Materials and methods), suggesting that no additional molecule(s) were necessary for the association between IRF-1 and NPM. In a control experiment, NPM was added to an EMSA reaction mixture along with another the transcriptional factor NF-IL6 (Akira et al., 1990) , but no eect on NF-IL6 binding was observed ( Figure 2a ). Moreover, we could not detect any eect on the NPM to DNA-binding activity of IRF-2 (data not shown), suggesting that NPM binding is IRF-1 speci®c. These facts next prompted us to examine the eect of NPM on the transcriptional activity of IRF-1. Luciferase assay revealed that NPM inhibited IRF-1-dependent transcriptional activity ( Figure 2b ). In contrast, b-actin promoter activity was not aected by NPM (data not shown). These results imply that NPM is an inhibitor of IRF-1.
The level of NPM mRNA is higher in clinical leukemia samples and leukemia cell lines
We have reported that the loss of functional IRF-1 may contribute to the development of MDS and leukemia (Willman et al., 1993; Harada et al., 1994b) . The above ®ndings directed us to assess the expression of NPM mRNA in leukemia samples. Compared with a sample from bone marrow cells from a healthy donor, six out of eight samples from leukemia patients exhibited almost two-to eight-times higher levels of NPM mRNA, and human-derived leukemia cell lines showed much higher levels, although the level of NPM mRNA seemed to have no relation with the clinical diagnosis ( Figure 3 ). These results suggest that high expression of NPM could contribute to the development of human leukemia by inactivating the surveillance function of the tumor-suppressor, IRF-1. The ability of NPM to inhibit IRF-1 binding to IRF-Es and the fact that it is highly expressed in leukemia cell lines is reminiscent of MDM2. MDM2 inhibits the physiological function of p53 and the MDM2 gene is often ampli®ed in human sarcomas (Oliner et al., 1992) . However, we have found no evidence of NPM gene ampli®cation in human leukemia cell lines (data not shown) suggesting that higher expression is due to increased transcription or mRNA stability.
NPM act as an oncogene
Previous experiments have shown that IRF-1 acts as a tumor suppressor Tanaka et al., 1994a, b) , and much evidence has accumulated that oncogenic proteins inactivate a function of tumor suppressor genes (Weinberg, 1991; Vogelstein and Kinzler, 1992) . These facts directed us to examine
Figure 2 (a) Electrophoretic mobility shift analysis (EMSA) with recombinant IRF-1 and NPM. Recombinant murine IRF-1 was incubated with nothing (IRF-1), GST (IRF-1 + GST) and GST-NPM (IRF-1 + GST-NPM) at 48C prior to EMSA using the IRF-E of the 2'-5' oligoadenylate synthetase probe. The same recombinant NPM was incubated with recombinant NF-IL6 and synthetic NF-IL6 binding site probe as a control experiment. After preincubation, EMSA was performed as previously described (Kawakami et al., 1995) . (b) Transcriptional activation by IRF-1 were inhibited by coexpression of NPM. P19 cell were cotransfected with 3 mg of luciferase reporter gene and 3 mg of eecter gene. Reporter genes are p-125luc, p2'-5'OASluc and pLdluc. Eecter genes are as follows: lanes 1, 5 and 9, 3 mg of pActC; lanes 2, 6 and 10, 1 mg of pAct 1 and 2 mg of pActC; lanes 3, 7 and 11, 1 mg of pAct 1, 1 mg of pAct NPM and 1 mg of pActC; lanes 4, 8 and 12, 1 mg of pAct1 and 2 mg of pActNPM. The luciferase activity by pAct1 alone was assigned to a value of 1.0. The analysis was performed in duplicate assays and the results were reproducible. The results are shown+s.d.
whether NPM can act as an oncogene, possibly by interfering with IRF-1 activity. NIH3T3 cells were transfected with pActNPM which contains the human NPM cDNA cloned downstream of the chicken b-actin gene promoter, and pActC, a control plasmid devoid of the cDNA insert, respectively. After G418 selection, stable transformants were established. We obtained three clones which expressed high levels of NPM mRNA (B8, B11, and B19). Compared with the control transformants (C1 and C3), NPM expressing cells showed no morphological change and grew at a rate similar to that of the controls, but reached a cell density that was about two times higher and exhibited anchorage-independent growth and tumorigenicity in nude mice (Table 2) , phenotypes similar to those observed in IRF-2-overexpressing NIH3T3 cells . The levels of mRNA of NPM were almost two times higher in the B8 and B11 clones and three times higher in the B19 clone than that in the control cells (Figure 4a) . Furthermore, the levels of NPM mRNA seemed to correlate with the extent of the transformed phenotype of the overexpressing clones. In addition, we detected that basal expression level of the lysyl oxidase gene, which has been identi®ed as one of target genes of IRF-1 (Tan et al., 1996) , was suppressed to about half of that observed in wild type cells in NPM overexpressing cells ( Figure  4b ), suggesting IRF-1 function is inhibited by NPM.
Discussion
In the present study we reported the identi®cation of an IRF-1 binding protein (IRF-BP), which is identical to NPM/B23/numatrin. NPM is reported to function in preribosomal particle assembly, and is also believed to play a role as a shuttle receptor for the nucleocytoplasmic transport of ribosomal components (Borer et al., 1989) . However in another context, NPM is reported to be an index of cell growth and cancer development (Chan et al., 1989) . Interestingly, both IRF-1 and NPM are regulated during cell cycle. The level of IRF-1 is the highest at G1 arrested phase (Bennett et al., 1985) . Lane 1, bone marrow (BM) cells from a healthy volunteer (NBM); lanes 2 ± 9, BM cells from leukemia patients; lanes 10 ± 12, human leukemia cell lines. CML-CP; chronic myelogenous leukemia in chronic phase, CML-BC; CML in blastic crisis, AML-M2; acute myeloblastic leukemia, AML-M5; acute monocytic leukemia; AML/MDS, leukemic transformation from myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; ALL-L2, acute lymphoblastic leukemia. NPM mRNA levels represent the relative amount of the NPM mRNA normalized to that of b-actin mRNA. The mRNA levels were quanti®ed by a Fuji BAS2000 image analyzer 0/6 0/6 2/6 4/6 6/6 4 to 6 4 to 6 3 to 6 *Cells were seeded at 2610 4 cells per 35-mm plate and grown in DMEM supplemented with 10% FCS and G418 (500 mg/ml). Medium was changed every 3 days and cells were counted every 24 h. Doubling time was determined by calculating the growth rate of exponentially growing cells. Saturation density is the number of cells 2 days after culture had reached con¯uency. Numbers are the means of duplicate assays +s.d. **Cells (10 5 cells) were mixed with 1.3% methylcellulose gel dissolved in culture medium and layered onto an agarose bed composed of 0.53% agarose and culture medium. Colonies were scored 3 weeks after plating. Each experiment was done in duplicate. A total of 500 cells were counted for each assay. #Four to six-week old nude mice (BALB/c nu/nu; Clea Japan, Inc.) were injected subcutaneously on both¯anks with 2610 6 cells resuspended in serum-free DMEM (200 ml). Cells were scored as tumorigenic if a visible nodule appeared at the site of injection and subcutaneously increased in size. Mice that did not develop tumors were observed for 6 weeks contrary NPM is induced at the early G1 phase and manifests the highest expression in the late G1 phase (Feuerstein et al., 1988) . Thus expression of NPM is the inverse of that of IRF-1, and might thereby function to amplify the eect of IRF-1 oscillation through the cell cycle. As mentioned before, IRF-2 expression is constant throughout the cell cycle .
The loss of IRF-1 function may contribute to carcinogenesis, as suggested by the transformation of NIH3T3 cells by IRF-2 overexpression , frequent loss of IRF-1 in some types of leukemia (Willman et al., 1993) , and increased susceptibility of IRF-1 7/7 cells to oncogenic transformation (Tanaka et al., 1994a) . In addition, the tumorsuppressor function of IRF-1 is abrogated when the DNA-binding domain of IRF-1 is disrupted (Harada et al., 1994b) . In the present study, we found that NPM could interfere with the ability of IRF-1 to bind to the IRF-Es, resulting in the inhibition of IRF-1-dependent transcriptional activity. In addition, overexpression of NPM causes the oncogenic transformation of NIH3T3. Thus NPM can serve as an oncogene and may function by inactivating the tumor suppressor activity of IRF-1. It is still unclear whether NPM is the only such regulator of IRF-1. Previously, a molecule designated TKO which interferes with the binding of members of the IRF family to their target sequences has been reported (Petricoin et al., 1994) . NPM is dierent from TKO in that its molecular size was reported to be 19 kDa and is thus much smaller than NPM. Thus, it is possible that several factors regulate IRF-1 activity in a more complex manner.
There is ample precedence for the notion that a protein might manifest oncogenic potential by inactivating a tumor suppressor. Viral oncoproteins, such as SV40 T angiten, and indigenous products can suppress the activity of p53 and Rb (reviewed in Weinberg, 1991) . MDM2 is one of the most well-known indigenous molecule which modulates p53 action. MDM2 has been shown to directly associate with p53, and excess MDM2 can abrogate transcriptional activation by p53 (reviewed by Vogelstein and Kinzler, 1992) . The signi®cance of this activity is emphasized by the ®nding that some human sarcomas exhibit ampli®cation of the MDM2 gene (Oliner et al., 1992) . In the present study, we found that NPM can bind to IRF-1 and inactivate its function, and that NPM itself has oncogenic potential. Although it is still unclear whether the oncogenic function of NPM is only limited to its inactivation of IRF-1, this is a novel ®nding showing than an oncogenic protein directly inhibits the function of IRF-1 by protein-protein interaction. These ®ndings suggest that NPM plays a role in a manner analogous to that of MDM2 inhibition of p53 action. In addition to MDM2 inactivating p53, p53 also activates the transcription of the MDM2 gene (Barak et al., 1993; Wu et al., 1993) . However, we found no evidence for a similar autoregulatory feedback loop functioning in the case of NPM and IRF-1, since NPM mRNA levels were unchanged in NIH3T3 cells overexpressing IRF-2 or IRF-1 7/7 EFs compared to control cells (data not shown).
The human IRF-1 gene is mapped to the human chromosome region 5q31.1, which is reported to be commonly deleted in samples from MDS and leukemia with 5q deletion or translocations (Willman et al., 1993) . In addition, the mRNA of IRF-1 is aberrantly spliced in a signi®cant number of leukemia and MDS patients not exhibiting 5q aberration (Harada et al., 1994b) . NPM has been reported to be overexpressed in hematopoietic cell lines and other cell lines (Feuerstein et al., 1988; Chan et al., 1989) . In our study NPM mRNA was found to be expressed almost two times higher in samples from leukemia patients versus healthy volunteers. Furthermore the expression was considerably higher in several human-derived leukemia cell lines. This ®nding supports the notion that the surveillance function of the tumor suppressor, IRF-1, is compromised in human cancer development by the overexpression of NPM.
Materials and methods
Expression and puri®cation of glutathione S-transferase fusion proteins
Escherichia coli (AD202; Nakao et al., 1994) was transfected by pGEX-3X, pFGShIRF-1 (a generous gift of Dr Hitoshi Ueda of Boehringer Ingelheim, Kawanishi, Japan) and pFGShNPM. Fresh overnight cultures transformed with above plasmids were diluted 1 : 30 in Luria Bertani (LB) broth for expression of GST and GST-NPM and in M9-Casamino acid broth for GST-IRF-1 containing ampicillin (25 mg/ml) and incubated for 4 h at 378C. After 2 h of growth, either isopropryl-b-thiogalactopyranoside (IPTG; Nacalai Tesque Inc., Kyoto, Japan) for GST and GST-NPM or 3-indoleacrylic acid (IAA; Nacalai Tesque Inc., Kyoto, Japan) for GST-IRF-1 was added to a ®nal concentration of 0.1 mM (IPTG) and 40 mg/ml (IAA) respectively.
Protein recovery using glutathione-Sepharose (Pharmacia) was performed as previously described (Kaelin et al., 1991) . Cell culture and radioisotope labeling
Exponentially growing suspension cultures of K-562 cells were pelleted by centrifugation and washed with phosphate-buered saline (PBS). For 35 S-labeling the cells were resuspended in methionine/cysteine-free RPMI medium supplemented with 10% (v/v) dialyzed FCS (1610 7 cells/ 10 cm dish) and incubated for 1 h. Subsequently the medium was changed to methionine/cysteine-free RPMI containing 10% (v/v) dialyzed FCS and 0.5 mCi of [ 35 S]methionine/cysteine (Expre35S35S Protein Labeling Mix, New England Nuclear) and incubated at 378C for 12 h. For cell cycle analysis, WI38 cell were cultured as previously described (Wiebel and Baserga, 1969) . Metabolically labeling was performed as described above except the time of incubation of 4 h. Cell synchronization was con®rmed by simultaneous [ 3 H]thymidine uptake assay.
Analysis and puri®cation of IRF-1 association molecule
After metabolically labeling of cells, nuclear and cytoplasmic extracts were prepared as previously described (Dignam et al., 1983) . The extracts were precleared by incubation with glutathione-Sepharose preloaded with GST. Each extracts were incubated with fusion proteins bound to beads at 48C and then washed ®ve times with NETN (20 mM Tris [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.1% NP-40). The beads were boiled in 16 sample buer and bound proteins resolved in SDS ± PAGE. Proteins were detected by autoradiography. For puri®cation of IRF-BP, nuclear extracts from almost 10 9 of K-562 cells were collected and after preclearing incubated with GST-IRF-1. Proteins bound to GST-IRF-1 were eluted with high salt condition (20 mM Tris [pH 8.0], 1 M NaCl, 1 mM EDTA, 0.1% NP-40), then precipitated by acetone precipitation method. Pellets were then resolved with 16 sample buer and electrophoresed in SDS ± PAGE. After separation of the proteins on the SDS ± PAGE, the gels were stained with Coomassie blue and a gel piece containing the band of IRF-BP was cut out and a protein was eluted out by electroelution method (Hunkapiller et al., 1983) .
Amino acid sequence of IRF-BP
Puri®ed IRF-BP was digested by lysyl endopeptidase and the resulting digests were fractionated by reverse phase high performance liquid chromatography on a C 18 column (218TP5215, 2.16150 mm, Vydac) using a linear gradient elution of acetonitrile in 0.1% tri¯uoroacetic acid. The isolated peptides were sequenced with a automated protein sequencer (477A, Applied Biosystems).
Construction of plasmids
To isolate NPM cDNA, total RNA was isolated from K-562 (Lozzio and Lozzio, 1975 ) cells with guanidiniumthiocyanate followed by centrifugation in cecium chloride solutions. Reverse transcription of NPM mRNA was followed by PCR ampli®cation with speci®c primers. Either 5' and 3' amplimer contained HindIII and XbaI site respectively. After digestion of PCR product with HindIII and XbaI, it was ligated into the HindIII ± XbaI backbone of pBluescript II SK + (Stratagene). To construct pFGShNPM, the following fragments were ligated; (i) TaqI ± XbaI blunt fragment of NPM cDNA (ii) BamHI ± SmaI backbone of pGEX-3X (Pharmacia) (iii) the following synthetic oligonucleotide: 5'-GATCATGGAA-GATT 3'-TACCTTCTAAGC. pActNPM was constructed by ligating the HindIII ± XbaI fragment of NPM into the HindIII ± XbaI backbone of pAct2 (Harada et al., 1990) .
Electrophoretic mobility shift analysis (EMSA)
Puri®ed GST and GST-NPM were collected as described above. Recombinant murine IRF-1 was produced and puri®ed as previously described (Miyamoto et al., 1988) . Prior to EMSA, IRF-1 was incubated at 48C with nothing, GST and GST-NPM respectively.
32 P-labeled IRF-E probe from human 2'-5' oligoadenylate synthetase gene (Kawakami et al., 1995) , 3.3 mg of herring sperm DNA and 2 mg of poly(dI-dC) were then added and incubated at 258C in a ®nal volume of 10 ml of a buer containing 10 mM TrisHCl (pH 7.5), 50 mM NaCl, 1 mM EDTA and 5% glycerol.
DNA transfection and luciferase assay
P19 embryonal carcinoma cells (2.5610 5 cells/6 cm dish) were used for luciferase assay. Transient DNA transfection was performed as previously described (Harada et al., 1990) . Eecters of expression vector were pAct1, pAct2 (Harada et al., 1990) , and pActNPM, and reporter genes were p-125luc, pOASluc and pLdluc. Each reporter gene contains the promoter region of human IFN-b gene, murine 2'-5' oligoadenylate synthetase gene and murine MHC class I gene upstream to the luciferase gene respectively (Harada et al., 1990) . Each assay was performed twice and the results were reproducible. Luciferase assays were done as previously described (Shibuya et al., 1994) .
Samples from leukemia patients and RNA blotting analysis Bone marrow samples from leukemia patients and a healthy volunteer were collected. Patients and a volunteer were informed that their bone marrow samples were obtained for research purposes, and their privacy would be protected. Bone marrow mononuclear cells were isolated with density sedimentation. RNA blotting analysis was performed as previously described (Harada et al., 1990) .
Establishment of NIH3T3 derived clones and transformation assay
15 mg of plasmid pActNPM were cotransfected with 0.3 mg of plasmid pSTneoB, which carries neo-resistance gene (Katoh et al., 1987) , into NIH3T3 cells. Control transfections were done with pActC. The condition of transfection, maintenance of cells and transformation assay were performed as previously described .
